Association of Chlamydia trachomatis Infection and Herpes Simplex Virus Type 2 Serostatus With Genital Human Papillomavirus Infection in Men: The HPV in Men Study

Imagem de Miniatura
Arquivos
art_VILLA_Association_of_Chlamydia_trachomatis_Infection_and_Herpes_Simplex_2013.PDF (512 KB)
Citações na Scopus
24
Tipo de produção
article
Data de publicação
2013
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
LIPPINCOTT WILLIAMS & WILKINS
Autores
ALBERTS, Catharina Johanna
LOEFF, Maarten F. Schim van der
PAPENFUSS, Mary R.
SILVA, Roberto Jose Carvalho da
LAZCANO-PONCE, Eduardo
NYITRAY, Alan G.
GIULIANO, Anna R.
Citação
SEXUALLY TRANSMITTED DISEASES, v.40, n.6, p.508-515, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Studies in women indicate that some sexually transmitted infections promote human papillomavirus (HPV) persistence and carcinogenesis. Little is known about this association in men; therefore, we assessed whether Chlamydia trachomatis (CT) infection and herpes simplex virus type 2 (HSV-2) serostatus are associated with genital HPV prevalence, an early event in HPV-related pathogenesis. Methods: Genital exfoliated cells, first-void urine, and blood from 3971 men recruited in the United States, Mexico, and Brazil were tested for HPV, CT, and HSV-2 antibodies, respectively. Multivariable logistic regression was used to assess the association of CT infection and HSV-2 serostatus with 4 HPV outcomes (any, oncogenic, nononcogenic only, and multiple infections). Results: A total of 64 (1.6%) men were CT positive, and 811 (20.4%) men were HSV-2 seropositive. After adjustment for potential confounders, CT was associated with any HPV (adjusted odds ratio [aOR], 2.19; 95% confidence interval [CI], 1.13-4.24), oncogenic HPV (aOR, 3.10; 95% CI, 1.53-6.28), and multiple HPV (aOR, 3.43; 95% CI, 1.69-6.95) prevalence. Herpes simplex virus type 2 serostatus was associated with any HPV (aOR, 1.25; 95% CI, 1.02-1.52), nononcogenic HPV only (aOR, 1.38; 95% CI, 1.08-1.75), and multiple HPV (aOR, 1.33; 95% CI, 1.06-1.68) prevalence. In analyses stratified by sexual behavior, CT infection was significantly associated with HPV detection among men reporting 2 or more recent sexual partners, whereas HSV-2 serostatus was significantly associated with HPV detection in men reporting 0 to 5 lifetime sexual partners. Conclusion: In this population, CT infection and HSV-2 serostatus were associated with prevalent genital HPV infection. Future prospective studies should investigate whether these infections influence HPV acquisition and/or persistence.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/1879
Referências
  1. Anttila T, 2001, JAMA-J AM MED ASSOC, V285, P47, DOI 10.1001/jama.285.1.47
  2. Arnheim DL, 2011, CANCER EPIDEM BIOMAR, V20, P2541
  3. Bouvard V, 2009, LANCET ONCOL, V10, P321
  4. Castellsague X, 2002, VIRUS RES, V89, P191, DOI 10.1016/S0168-1702(02)00188-0
  5. Castle PE, 2003, SEX TRANSM DIS, V30, P575, DOI 10.1097/00007435-200307000-00009
  6. Castle PE, 2003, J NATL CANC I MONOGR, V31, P29
  7. Giuliano AR, 2009, INT J CANCER, V124, P1251, DOI 10.1002/ijc.24097
  8. Giuliano AR, 2011, LANCET, V377, P932, DOI 10.1016/S0140-6736(10)62342-2
  9. Gravitt PE, 2000, J CLIN MICROBIOL, V38, P357
  10. Gravitt PE, 1998, J CLIN MICROBIOL, V36, P3020
  11. Howell-Jones R, 2012, VACCINE, V30, P3867, DOI 10.1016/j.vaccine.2012.04.006
  12. Kim S, 2011, SEX TRANSM DIS, V38, P587, DOI 10.1097/OLQ.0b013e31820a9324
  13. Kjaer SK, 2005, CANCER EPIDEM BIOMAR, V14, P1528, DOI 10.1158/1055-9965.EPI-04-0754
  14. KOFFA M, 1995, INT J CANCER, V63, P58, DOI 10.1002/ijc.2910630112
  15. Lehtinen M, 2011, SEX TRANSM INFECT, V87, P372, DOI 10.1136/sti.2010.044354
  16. Lehtinen M, 2002, AM J EPIDEMIOL, V156, P687, DOI 10.1093/aje/kwf098
  17. Manavi K, 2006, BEST PRACT RES CL OB, V20, P941, DOI 10.1016/j.bpobgyn.2006.06.003
  18. Oakeshott P, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e4168
  19. Safaeian M, 2010, J NATL CANCER I, V102, P1794, DOI 10.1093/jnci/djq436
  20. Samoff E, 2005, AM J EPIDEMIOL, V162, P668, DOI 10.1093/aje/kwi262
  21. Shigehara K, 2011, J INFECT CHEMOTHER, V17, P487, DOI 10.1007/s10156-010-0203-0
  22. Smith JS, 2004, INT J CANCER, V111, P431, DOI 10.1002/ijc.20257
  23. Smith JS, 2010, INT J CANCER, V126, P572, DOI 10.1002/ijc.24770
  24. Smith JS, 2002, J NATL CANCER I, V94, P1604
  25. Tran-Thanh D, 2003, AM J OBSTET GYNECOL, V188, P129, DOI 10.1067/mob.2003.66
  26. Veldhuijzen NJ, 2012, SEX TRANSM DIS, V39, P128, DOI 10.1097/OLQ.0b013e3182367c4c
  27. Vriend HJ, 2012, SEX TRANSM DIS, V39, P72, DOI 10.1097/OLQ.0b013e318235b3b0
  28. Wald A, 2002, J INFECT DIS, V186, pS34, DOI 10.1086/342969
  29. Wald A, 2002, CLIN INFECT DIS, V35, pS173, DOI 10.1086/342104
  30. WHO, 2007, IARC MON EV CARC RIS, V90

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - LIM/24